Refine by
Clinical Outcome Articles & Analysis
245 news found
The use of the exoscope resulted in shorter operative time, reduced blood loss, shorter length of stay and favorable clinical outcomes compared to the use of the operative microscope: 19% reduction in operative time (83 mins vs 132 mins; p=0.006) 40% reduction in length of stay (1.04 days vs 1.73 days; p=0.02) 79% reduction in blood loss (28 ml vs 132 ml; ...
With curated data from the entire surgical care process, Medtech industry partners gain meaningful insight into the critical factors that can affect outcomes and improve clinical quality for patients. This data also provides tremendous value back to hospital partners and clinicians as Caresyntax provides data science reporting and analysis back to hospitals for ...
“Additionally, this partnership will provide important insights about the impact of innovative technology and advanced healthcare solutions on real-world patient outcomes.” DYANAVEL XR extended-release tablets are approved for the treatment of ADHD in patients aged 6 years and older. ...
With more than 60 years’ expertise in respiratory diagnostics, Vitalograph is the only company in the world specialized in delivering clinical trial services exclusively for pulmonary function-focused studies. Speaking about the recent additions to their portfolio of services, Richard James, Executive Vice President and Chief Operating Officer of Vitalograph Clinical Trials says: ...
Additionally, the darolutamide combination showed consistent benefits across clinically relevant secondary endpoints, with the overall incidence of treatment-emergent adverse events being similar between treatment arms. “The approval of Nubeqa in mHSPC in Europe is a major step forward for patients and their treating physicians, expanding the treatment options available ...
ByBayer AG
Now more than ever, it is clear that these present a large percentage of false positive and negative results, significantly hampering the fight against the epidemic and negatively impact clinical outcomes. Alertgy’s coronavirus technology will enable a viral particle detection method which will afford several significant advantages in detecting infected ...
ByAlertgy
The companies will jointly develop the compounds for the multiple system atrophy (MSA) and Parkinson’s disease (PD) indications based on early-stage clinical studies, and consider exploring additional indications based on clinical outcomes. ...
Cellworks biosimulation results may provide guidance for additional indications to target for clinical development. “Ninety percent of drug candidates fail to make it to the marketplace because of failed clinical development strategies,” said Dr. ...
We performed 2 clinical trials in leading neurorehabilitation hospitals in Germany and Spain proving safety, feasibility and usability of the exoskeleton in a clinical setting, and showing significant improvements in clinical outcomes and benefits in rehabilitation. A Multicentric Clinical investigation in ...
Evaluation of intranasal LMN-301 efficacy in a hamster SARS-CoV-2 challenge model. Body weight (left panel) and clinical scores (right panel) were the primary outcomes of interest. Animals were treated with LMN-301 or saline solution and monitored for 7 days. ...
By identifying which patients will not respond to HMA, clinicians can consider other options such as a combination therapy or a clinical trial.” Biosimulation of MDS using differentiation scoring was able to identify patients with minimal benefits from HMA for whom an alternative strategy at the outset of treatment could offer a very meaningful chance to enhance ...
Starton Therapeutics Inc., (the “Company”) a clinical stage biotechnology company announced today results from a 28-day efficacy study of STAR-LLD continuous subcutaneous (SC) infusion versus intraperitoneal (IP) lenalidomide in immunomodulatory drug (IMiD)-resistant RPMI CB.17 SCID mice. ...
” Amit Rushi brings over two decades of medical device and digital health experience to Bodyport, with expertise in building and leading world-class commercial teams, a track record of successful product launches, and translating health technology innovation into market adoption and clinical impact. Before joining Bodyport, Amit served as the Vice President, Commercial at ...
The Motion Speed mode is synonymous with patient comfort, treatment speed and clinical outcome. Combining the cooling of the skin with repeated laser pulses up to a frequency of 10 pulses per second, without the risk of side effects and in the absence of discomfort when compared to other lasers and pulsed lights on the market. ...
Zuranolone 50 mg demonstrated a clinically meaningful and statistically significant improvement in depressive symptoms at Day 15, the primary endpoint, and at Days 3, 28, and 45, key secondary endpoints as previously reported Newly presented data offered additional insight into the SKYLARK Study and further demonstrated the rapid improvements in depressive symptoms observed in ...
Reynolds, cardiac electrophysiologist at Lahey Hospital & Medical Center and Baim Institute for Clinical Research. mSToPS was a landmark direct-to-participant randomized clinical trial combined with a prospective matched observational cohort study. ...
The two xCures posters will be presented at the Poster Session on Friday, November 18, 2022, from 7:30 pm-9:30 pm EST, and are entitled: EPCO-10: Systems biology-based therapeutic predictions with gbmSYGNAL and clinical correlates in the real-world longitudinal outcomes registry XCELSIOR Timothy J. ...
ByxCures
” Over the last two decades, disease activity in rheumatoid arthritis (RA) has improved, yet fatigue and pain continue to hinder patients’ quality of life (QOL), and ability to function.2,3 Less than 30% of patients are satisfied with their pain levels and 40-80% of RA patients are affected by fatigue.4,5 Pain and fatigue have negative impacts on mental and physical QOL, including ...
To shape our portfolio of innovative drugs with accelerated time-to-market, we intend to combine internal innovation with smart business development and apply deep clinical expertise to push programs through an optimal development process. ...
ITM-11 is being evaluated as a Targeted Radionuclide Therapy in two phase III clinical trials, COMPETE and COMPOSE. The FDA Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and address an unmet medical need. ...